Report : South America ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)
At 2.3% CAGR, the South America ECMO Market is speculated to be worth US$ 60.58 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the SAM ECMO market was valued at US$ 53.00 million in 2022 and is expected to reach US$ 60.58 million by 2028, registering a CAGR of 2.3% from 2022 to 2028. Increasing survival rates with ECMO and growing adoption of ECMO in lung transplantation procedures are the critical factors attributed to the SAM ECMO market expansion.
The employment of ECMO for treating respiratory failure has been increasing in recent years, as treatments with ECMO are showing promising survival rates. Further, ECMO is recommended to treat patients suffering from acute respiratory distress syndrome (ADRS), primary graft dysfunction post lung transplant, and trauma to the lungs as it increases the survival rate of patients. Furthermore, ECMO increases the survival rate of patients affected by post-cardiac arrest regimen. Radical shift in adopting westernized lifestyles leads to various cardiac disorders. This leads the key players to invest significantly in R&D, which results in the improved treatment outcomes with ECMO with increased survival rate. Thus, the rising survival rate with the use of ECMO in various treatments is expected to have more market opportunities during the forecast period.
On the contrary, complications associated with ECMO hurdles the growth of SAM ECMO market.
Based on modality, the SAM ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held 43.0% market share in 2022, amassing US$ 22.81 million. It is projected to garner US$ 26.96 million by 2028 to expand at 2.8% CAGR during 2022–2028.
Based on application, the SAM ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held 56.6% market share in 2022, amassing US$ 30.00 million. It is projected to garner US$ 33.52 million by 2028 to expand at 1.9% CAGR during 2022–2028.
Based on age group, the SAM ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held 40.7% market share in 2022, amassing US$ 21.59 million. It is projected to garner US$ 25.52 million by 2028 to expand at 2.8% CAGR during 2022–2028.
Based on country, the SAM ECMO market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil captured 62.0% market share in 2022. It was assessed at US$ 32.88 million in 2022 and is likely to hit US$ 38.20 million by 2028, exhibiting a CAGR of 2.5% during the forecast period.
Key players dominating the SAM ECMO market are ABIOMED Inc, Braile Biomedica, Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group among others.
- In May 2022, LivaNova PLC Acquired ALung Technologies, Inc. ALung Technologies, Inc., is a provider of low-flow extracorporeal carbon dioxide removal technologies for treating patients with acute respiratory failure.
- In April 2020, Abiomed acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. With the acquisition of Cardiopulmonary Support Technology (ECMO), the company expanded its product portfolio.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: email@example.com